Taysha Gene Therapies (TSHA) Debt to Equity (2022 - 2025)
Taysha Gene Therapies (TSHA) has disclosed Debt to Equity for 4 consecutive years, with $0.2 as the latest value for Q4 2025.
- Quarterly Debt to Equity fell 66.97% to $0.2 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.2 through Dec 2025, down 66.97% year-over-year, with the annual reading at $0.2 for FY2025, 66.97% down from the prior year.
- Debt to Equity hit $0.2 in Q4 2025 for Taysha Gene Therapies, down from $0.23 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $40.01 in Q4 2022 to a low of -$3.65 in Q3 2023.
- Historically, Debt to Equity has averaged $2.64 across 4 years, with a median of $0.51 in 2023.
- Biggest five-year swings in Debt to Equity: plummeted 446.49% in 2023 and later surged 133.63% in 2024.
- Year by year, Debt to Equity stood at $40.01 in 2022, then plummeted by 98.65% to $0.54 in 2023, then increased by 13.65% to $0.61 in 2024, then plummeted by 66.97% to $0.2 in 2025.
- Business Quant data shows Debt to Equity for TSHA at $0.2 in Q4 2025, $0.23 in Q3 2025, and $0.17 in Q2 2025.